TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01263028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol supplementation
Description: Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
Study: NCT04108260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albutrepenonacog Alfa 1 UNT [IDELVION]
Description: Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
Study: NCT03888482

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Investigational daily disposable soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Investigational daily disposable soft contact lenses
Study: NCT04760548

Intervention type: OTHER
Intervention: Observational study

Intervention type: OTHER
Intervention: Observational study

Intervention type: OTHER
Intervention: Observational study
Study: NCT04361110

Intervention type: RADIATION
Intervention: Computerized tomography scan of the abdomen
Description: Non-specific abdominal ct´s with different phases and contrast +/-.

Intervention type: RADIATION
Intervention: Computerized tomography scan of the abdomen
Description: Non-specific abdominal ct´s with different phases and contrast +/-.
Study: NCT03888482

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Commercially available daily disposable soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Commercially available daily disposable soft contact lenses
Study: NCT02438085

Intervention type: OTHER
Intervention: prospective collection of data and follow-up
Description: prospective collection of data and follow-up of all patients admitted to hospital for ACS
Study: NCT02510599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solithromycin
Study: NCT02646436

Intervention type: OTHER
Group type: OTHER
Intervention: HD treatment
Description: Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.

Intervention type: OTHER
Group type: OTHER
Intervention: PD treatment
Description: Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
Study: NCT00825175

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supramalleolar Orthoses
Description: In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
Study: NCT03657407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belladonna Opium
Description: Belladonna Opium 16.2-60mg rectal suppository

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Glycerin Suppository
Description: Glycerine rectal suppository
Study: NCT04958590

Intervention type: RADIATION
Intervention: whole spine X-ray
Description: Group 1 underwent whole spine X-ray in standing and sitting positions.

Intervention type: RADIATION
Intervention: whole spine X-ray
Description: Group 1 underwent whole spine X-ray in standing and sitting positions.
Study: NCT03468946

Intervention type: OTHER
Group type: OTHER
Intervention: salty taste perception
Description: salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk ).

Intervention type: OTHER
Group type: OTHER
Intervention: salty taste perception
Description: salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk ).

Intervention type: OTHER
Group type: OTHER
Intervention: salty taste perception
Description: salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk ).
Study: NCT03251404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury prevention exercise programs
Description: The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
Study: NCT02366130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ra-223 dichloride
Description: 55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Therapy
Description: A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
Study: NCT04201405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
Description: Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
Study: NCT04934774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR T cells
Description: Non-gene edited anti-CD7 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study: NCT04063137

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin fortified bread with beef patty (35% fat)
Description: Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Anthocyanin fortified bread with beef patty (35% fat)
Description: Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
Study: NCT03512158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive respiratory support mode
Description: A mode of providing respiratory support via nasal masks or prongs
Study: NCT02256774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS
Study: NCT03512158

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive respiratory support mode
Description: A mode of providing respiratory support via nasal masks or prongs
Study: NCT03947021

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scan
Description: A CT scan of thorax and heart will be performed in the CT+BSPM group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body-surface potential mapping
Description: Measurement of 256-lead body-surface electrocardiogram

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body-surface potential mapping
Description: Measurement of 256-lead body-surface electrocardiogram
Study: NCT03306290

Intervention type: DRUG
Group type: OTHER
Intervention: Serum dosage of antibiotic prophylaxis CEFOXITIN
Description: Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~1. Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (\~30 min), 1 tube (5 ml) of blood will be withdrawn~2. Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~3. Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn
Study: NCT02223130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy techniques
Description: Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
Study: NCT01217515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 4% cream
Description: 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem hydrochloride 2% cream
Description: 3 times daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times daily
Study: NCT00362323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate (F) + metformin (M) hydrochloride fixed combination
Description: F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
Study: NCT02978768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Description: Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
Study: NCT03728361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02951598

Intervention type: DRUG
Intervention: Florbetapir F 18 PET Scan
Description: Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.

Intervention type: DRUG
Intervention: Florbetapir F 18 PET Scan
Description: Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.

Intervention type: DRUG
Intervention: Florbetapir F 18 PET Scan
Description: Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.

Intervention type: DRUG
Intervention: Florbetapir F 18 PET Scan
Description: Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
Study: NCT01674764

Intervention type: PROCEDURE
Intervention: Early surgical intervention
Description: Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation

Intervention type: PROCEDURE
Intervention: Late surgical intervention
Description: Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
Study: NCT04652362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset Online Single-Session Intervention
Description: During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy Online Single-Session Intervention (Control)
Description: The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
Study: NCT03830138

Intervention type: GENETIC
Intervention: Oxidized-LDL gene polymorphism
Description: Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA

Intervention type: GENETIC
Intervention: Oxidized-LDL gene polymorphism
Description: Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
Study: NCT01936246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Increased protein
Study: NCT06170255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Description: Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
Study: NCT02978768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physico-Mental rehabilitation Wii
Description: Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
Study: NCT04488094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FSPG
Description: A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FSPG
Description: A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
Study: NCT00291226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Glycine 0.4 g/kg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02801773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment Gingivitis with Probiotic
Description: Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Gingivitis conventional
Description: gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
Study: NCT03432962

Intervention type: OTHER
Intervention: no intervention - recoding of food recall only
Description: recoding of food recall
Study: NCT01280500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: electronic medical record
Description: Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Approach to Care
Description: Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: No EMR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shared Decision Making
Description: The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: school based care
Description: the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
Study: NCT00025233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01363830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-Week Post-Operative Restriction
Description: Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Six-Week Post-Operative Restriction
Description: Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
Study: NCT03087357

Intervention type: OTHER
Intervention: SmartNIPT
Description: A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.

Intervention type: OTHER
Intervention: SmartNIPT
Description: A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
Study: NCT02926612

Intervention type: OTHER
Intervention: Next Generation Genomic Sequencing
Description: DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
Study: NCT02058277

Intervention type: DRUG
Group type: OTHER
Intervention: bosutinib or bosutinib + aprepitant
Description: Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
Study: NCT00133211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Pulmonary vein isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Pulmonary vein isolation
Study: NCT00651807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etonogestrel
Description: Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every day one tablet up to 8 weeks
Study: NCT02345577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention
Description: Physiotherapeutical intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention
Description: Sham physiotherapeutical intervention
Study: NCT02655809

Intervention type: RADIATION
Group type: OTHER
Intervention: Fluoroscopic examination
Study: NCT02410174

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study: NCT01712074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377 (SAM-760)
Description: 30 mg QD of PF-05212377 (SAM-760)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD
Study: NCT04619173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Description: hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy Program
Description: hot pack ,transcutaneous electrical nerve stimulation and stretching
Study: NCT00093223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Nanoparticle Albumin Bound
Description: Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Nanoparticle Albumin Bound
Description: Single or duel doses of 35mg/m\^2 ABI-007, administered IV, administered after placement of denovo stent(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Nanoparticle Albumin Bound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Nanoparticle Albumin Bound
Description: 35mg/35 infusion time is 3.5 minutes
Study: NCT01472835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Used for anxiolysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Used for analgesia and as a sedative